Clinical trials: Diabetic Macular Oedema
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Evaluation of IBI302 Injection in nAMD or DME
The purpose of this study is to determine the efficacy and safety of intravitreal IBI302 in the treatment of subjects with neovascular age-related macular degeneration (only in Phase I) or diabetic macular edema.
- Trial name
- NCT05961007
- Testing
- Intravitreal injection of IBI302(dose 1), Intravitreal injection of IBI302(dose 2), Intravitreal injection of IBI302(dose 3)
- Where
- China
- Volunteers
- 234 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Diabetic Macular Edema
Ranibizumab 0.5 mg for Diabetic Macular Edema With Initial Intensive Treatment in the Real World Clinical Setting in Korea (Rising K)
This study was a multicenter, non-interventional, retrospective chart review of patients with DME who received ranibizumab 0.5 mg as initial intensive treatment in real-world clinical setting in Korea.
- Trial name
- NCT05815212
- Where
- South Korea
- Volunteers
- 87 people
- Sponsor
- Novartis Pharmaceuticals
Retinopathy, Diabetic
A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema
The purpose of this study is to characterize the systemic and ocular safety and tolerability, pharmacokinetics, exploratory efficacy and pharmacodynamics of 3 months of repeat administration of oral darapladib in diabetic macular…
- Trial name
- NCT01506895
- Testing
- darapladib
- Where
- 16 sites in Australia, Denmark and 3 more
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Diabetic Macular Edema (DME)
A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema
The purpose of this study is to learn about the effects of BGE-102 on change in vision in participants with center-involved diabetic macular edema (CI-DME).
- Trial name
- QUELL-DME (NCT07812090)
- Testing
- Oral BGE-102, Anti-VEGF
- Where
- 16 sites in United States
- Volunteers
- 180 people
- Sponsor
- BioAge Labs, Inc.
Diabetic Macular Edema
A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema
This is a multiple-center, multiple-dose, randomized, active comparator-controlled, double-masked, three parallel group, 36-week study in participants with center-involving diabetic macular edema (DME).
- Trial name
- BOULEVARD (NCT02699450)
- Testing
- Faricimab, Ranibizumab
- Where
- 60 sites in United States
- Volunteers
- 229 people
- Sponsor
- Hoffmann-La Roche
Diabetic Macular Edema
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)
This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W)…
- Trial name
- NCT03622580
- Testing
- Aflibercept, Faricimab
- Where
- 185 sites in United States, Austria and 14 more
- Volunteers
- 940 people
- Sponsor
- Hoffmann-La Roche
Diabetic Retinopathy, Diabetic Eye Problems
Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool
More than 29 million people in the US are living with diabetes, many of whom will develop diabetic retinopathy (DR) or diabetic macular edema (DME) collectively known as diabetic eye disease (DED), the leading cause of vision…
- Conditions
- Diabetic Retinopathy, Diabetic Eye Problems, Diabetic Macular Edema
- Trial name
- NCT03112005
- Testing
- Color fundus photography, Mydriatic Agent
- Where
- United States
- Volunteers
- 942 people
- Sponsor
- Eyenuk, Inc.
Diabetic Macular Oedema
A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME）
The study is designed for multi-center,randomized,double-masked,active-contralledstudy to evaluate effective and security of intravitrealinjection of IBI302 in subjects with Diabetic Macular Oedema.
- Trial name
- NCT06908876
- Testing
- IBI302, Faricimab
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Innovent Biologics Technology Limited (Shanghai R&D Center)
Visual Impairment Due to Diabetic Macular Edema
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema
This study was designed to confirm the efficacy and safety of laser photocoagulation as adjunctive therapy to ranibizumab 0.5 mg versus laser monotherapy in patients with visual impairment due to Diabetic Macular Edema.
- Trial name
- RELATION (NCT01131585)
- Testing
- Active laser photocoagulation, Ranibizumab 0.5 mg
- Where
- 34 sites in Germany
- Volunteers
- 128 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy, Macular Oedema
Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment
This study evaluates a new investigational treatment regimen of three consecutive monthly doses of ranibizumab followed by an as-needed treatment regimen, with monthly follow-up for the first three months then two-monthly…
- Trial name
- RELIGHT (NCT01257815)
- Testing
- Ranibizumab
- Where
- 15 sites in United Kingdom
- Volunteers
- 111 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic Macular Edema
This study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone with laser treatment vs. laser treatment alone in patients with diabetic macular edema.
- Trial name
- NCT00464685
- Testing
- Dexamethasone, Laser Photocoagulation
- Where
- 2 sites in United States, Canada
- Volunteers
- 253 people
- Sponsor
- Allergan
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration
A study to evaluate safety, tolerability, and pharmacokinetics of a single intravitreal injection of UBX1325 in patients diagnosed with diabetic macular edema (DME) or neovascular Age-Related Macular Degeneration.
- Trial name
- NCT04537884
- Testing
- UBX1325
- Where
- 8 sites in United States
- Volunteers
- 19 people
- Sponsor
- Unity Biotechnology, Inc.
Diabetic Macular Edema
Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)
This is a clinical study where patients with diabetes and a vision threatening eye condition called "Diabetic Macular Edema" receive four injections into the eye at monthly intervals.
- Trial name
- NCT03466099
- Testing
- KVD001 Injection
- Where
- 35 sites in United States
- Volunteers
- 129 people
- Sponsor
- KalVista Pharmaceuticals, Ltd.
Diabetic Macular Edema
Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema
This study is designed to demonstrate the safety and tolerability of suprachoroidal CLS-TA alone or in combination with intravitreal aflibercept in subjects with diabetic macular edema associated with diabetes mellitus.
- Trial name
- HULK (NCT02949024)
- Testing
- IVT Aflibercept, SC CLS-TA
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Clearside Biomedical, Inc.
Diabetic Macular Edema
Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)
This study is designed to assess safety and efficacy of intravitreal injection of Conbercept on visual acuity and anatomic outcomes in patients with diabetic macular edema (DME) .
- Trial name
- NCT02194634
- Testing
- Conbercept, Laser
- Where
- 17 sites in China
- Volunteers
- 248 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Diabetic Macular Edema
Ranibizumab "Treat and Extend" in Diabetic Macular Edma
This study is designed to explore a more individualized treatment regime based on achievement of disease stability to define a personal optimal treatment interval with ranibizumab in patients with visual impairment due to…
- Trial name
- OPTIMAL (NCT01297569)
- Testing
- Ranibizumab
- Where
- Norway
- Volunteers
- 7 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.
The purpose of this study is to generate additional safety and effectiveness data in Indian Diabetic macular edema (DME) patients that more closely resemble the real-world population intended to be treated with Brolucizumab.
- Trial name
- NCT05959304
- Testing
- brolucizumab
- Where
- 8 sites in India
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion
Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy
This is a single-arm, multicenter study to evaluate clinical usability of a pre-filled syringe containing SCD411 in adult patients with neovascular Wet Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO)…
- Conditions
- Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, Diabetic Retinopathy
- Trial name
- NCT07501052
- Testing
- SCD411 0.05mL (2mg)
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Sam Chun Dang Pharm. Co. Ltd.
Diabetic Macular Edema
Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection
This was a primary data collection-based observational special drug-use surveillance to be conducted in accordance with the Good Post-marketing Study Practice (GPSP) ordinance.
- Trial name
- NCT05526729
- Testing
- Beovu
- Where
- 76 sites in Japan
- Volunteers
- 222 people
- Sponsor
- Novartis Pharmaceuticals
Retinal Vein Occlusion, Age Related Macular Degeneration
Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.
Ranibizumab is a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody fragment approved in Chile by the Instituto de Salud Pública for the treatment of diabetic macular edema (DME), retinal vein occlusion…
- Trial name
- NCT02140411
- Testing
- Ranibizumab Intravitreal injections
- Where
- Chile
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals